Data Sheet (Cat.No.T2226)



Pergolide mesylate

Chemical Properties

CAS No.: 66104-23-2

Formula: C20H30N2O3S2

Molecular Weight: 410.59

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Pergolide mesylate salt(LY127809) is a long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.
Targets(IC50)	5-HT Receptor,Adrenergic Receptor,Dopamine Receptor

Solubility Information

Solubility	DMSO: 55 mg/mL (133.95 mM), Sonication is recommended.	
	H2O: 40 mg/mL (97.4 mM),Sonication is recommended.	
	(< 1 mg/ml refers to the product slightly soluble or insoluble)	

Preparing Stock Solutions

	1mg	5mg	10mg	
1 mM	2.4355 mL	12.1776 mL	24.3552 mL	
5 mM	0.4871 mL	2.4355 mL	4.871 mL	
10 mM	0.2436 mL	1.2178 mL	2.4355 mL	
50 mM	0.0487 mL	0.2436 mL	0.4871 mL	

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Franks, S., et al., Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia. British medical journal (Clinical research ed.), 1983. 286(6372): p. 1177.

Koller, W.C., et al., The pharmacological evaluation of pergolide mesylate as a potential anti-parkinson agent. Neuropharmacology, 1980. 19(9): p. 831-7.

Lemberger, L. and R.E. Crabtree, Pharmacologic effects in man of a potent, long-acting dopamine receptor agonist. Science, 1979. 205(4411): p. 1151-3.

Schade, R., et al., Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med, 2007. 356(1): p. 29-38.

Page 1 of 2 www.targetmol.com

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com